ELK1 inhibition alleviates amyloid pathology and memory decline by promoting the SYVN1-mediated ubiquitination and degradation of PS1 in Alzheimer’s disease. This evidence concerns the gene PSEN1 and early-onset autosomal dominant Alzheimer disease.